Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
03 May 2018Website:
http://unitybiotechnology.comNext earnings report:
13 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | 7 min agoDividend
Analysts recommendations
Institutional Ownership
UBX Latest News
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the third quarter ended September 30, 2024.
UNITY Biotechnology (UBX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the second quarter ended June 30, 2024.
SAN FRANCISCO, July 22, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced the appointment of Alicia Tozier, MBA, as chief strategy officer. In this new role, she will develop and implement the company's corporate and product strategies.
There is increasing optimism about UNITY Biotechnology's earnings prospects, leading to its upgrade to a Zacks Rank #2 (Buy) and potential for a rise in stock price.
Unity's (UBX) phase II ENVISION study on UBX1325 fails to meet the non-inferiority threshold compared to aflibercept through 24 weeks in the wet AMD study.
Unity Biotechnology (NASDAQ: UBX ) stock is taking a beating on Monday after revealing results from its Phase 2 clinical trial of UBX1325. UBX1325 is a treatment in development by the company that it's testing for use with patients suffering from wet age-related macular degeneration ( AMD ).
What type of business is Unity Biotechnology?
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
What sector is Unity Biotechnology in?
Unity Biotechnology is in the Healthcare sector
What industry is Unity Biotechnology in?
Unity Biotechnology is in the Biotechnology industry
What country is Unity Biotechnology from?
Unity Biotechnology is headquartered in United States
When did Unity Biotechnology go public?
Unity Biotechnology initial public offering (IPO) was on 03 May 2018
What is Unity Biotechnology website?
https://unitybiotechnology.com
Is Unity Biotechnology in the S&P 500?
No, Unity Biotechnology is not included in the S&P 500 index
Is Unity Biotechnology in the NASDAQ 100?
No, Unity Biotechnology is not included in the NASDAQ 100 index
Is Unity Biotechnology in the Dow Jones?
No, Unity Biotechnology is not included in the Dow Jones index
When was Unity Biotechnology the previous earnings report?
No data
When does Unity Biotechnology earnings report?
The next expected earnings date for Unity Biotechnology is 13 November 2024